atezolizumab
roche
['atezo']
dr. kim w/ scarce-prodige 60 p2 study, dcf +/- atezo as 1l anal cancer: 12-month pfs was 44.2 vs 43.2%. orr 74.6 vs 78.1%. g3 toxicities 59.0 vs 36.4% #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.